APA (7th ed.) Citation

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., . . . Kosiborod, M. N. (2021). The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nature medicine, 27(11), 1954-1960. https://doi.org/10.1038/s41591-021-01536-x

Chicago Style (17th ed.) Citation

Nassif, Michael E., et al. "The SGLT2 Inhibitor Dapagliflozin in Heart Failure with Preserved Ejection Fraction: A Multicenter Randomized Trial." Nature Medicine 27, no. 11 (2021): 1954-1960. https://doi.org/10.1038/s41591-021-01536-x.

MLA (9th ed.) Citation

Nassif, Michael E., et al. "The SGLT2 Inhibitor Dapagliflozin in Heart Failure with Preserved Ejection Fraction: A Multicenter Randomized Trial." Nature Medicine, vol. 27, no. 11, 2021, pp. 1954-1960, https://doi.org/10.1038/s41591-021-01536-x.